Publications by authors named "Areum Gil"
Article Synopsis
- Heterologous boost regimens involving an mRNA vaccine after a DNA vaccine are gaining interest for enhancing immunity against SARS-CoV-2.
- In a clinical trial with 32 participants, those who received an mRNA vaccine 6 to 8 months after the GLS-5310 DNA vaccine reported no adverse events, indicating a good safety profile.
- The study found significant improvements in immune responses, with increased antibody and T-cell levels, marking it as the first report on immune responses from this specific vaccination strategy.
pGO-1002, a non-viral DNA vaccine that expresses both spike and ORF3a antigens of SARS-CoV-2, is undergoing phase 1 and phase 2a clinical trials in Korea and the US. A preclinical repeated-dose toxicity study in New Zealand white rabbits in compliance with Good Laboratory Practice (GLP) was conducted to assess the potential toxicity, local tolerance, and immunogenicity of the vaccine and GeneDerm suction device. The dose rate was 1.
View Article and Find Full Text PDFArticle Synopsis
- The CoV2-001 phase I trial tested the GLS-5310 DNA vaccine for safety and immune response over 48 weeks with 45 participants who had not previously been vaccinated.* -
- Participants received two doses of the vaccine, administered intradermally at varying doses and intervals, and the vaccine was found to be well-tolerated with no serious side effects.* -
- The results showed high antibody and T cell responses, with 95.5% of participants producing anti-spike antibodies and 97.8% showing T cell responses, highlighting the vaccine's strong immunogenicity compared to other vaccines.*